EA Electronic Arts Inc.

Fight for a New Home in Mass Effect: Andromeda

Today Electronic Arts Inc. (NASDAQ:EA) and BioWare™ announced that Mass Effect™: Andromeda, the latest edition of the award-winning franchise, is available now on Origin™ for PC, Xbox One and PlayStation®4 in North America and starting March 23rd in Europe. Mass Effect: Andromeda takes players far beyond the Milky Way to the uncharted Andromeda galaxy where a new cast of characters, led by Ryder, will fight for a new home for humanity. Playing as one of the Ryder siblings in the role of the Pathfinder, players will lead a squad of highly-trained explorers as they search for and discover new worlds, alien races and threats.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170321005519/en/

Fight for a New Home in Mass Effect: Andromeda (Photo: Business Wire)

Fight for a New Home in Mass Effect: Andromeda (Photo: Business Wire)

“We’re very happy to welcome the fans back to the Mass Effect universe,” said Aaryn Flynn, VP and GM of BioWare. “The team’s vision for this epic new chapter was to take what our fans love about Mass Effect – great characters and combat – and add more emphasis on exploration while telling a different type of story. We’re following a group of characters who are just starting their heroic journey, and we can’t wait for our fans to discover more about them and this new galaxy.”

The story opens after a 600-year journey to the Andromeda galaxy, as the crew begins searching for a new home for humanity. The dreams of easy settlement are quickly shattered, as worlds expected to be paradises are instead wastelands, and the Pathfinder discovers that not all inhabitants of the galaxy welcome humanity. Terrifying enemies will challenge players and their crew, forcing them to utilize destructible environments, vertical movement through boosted jumps, customizable weapons, Biotics and other tools in their arsenal to even the playing field in a combat system and character progression that is more thrilling and open than ever.

Mass Effect: Andromeda will also feature a separate team-based online multiplayer mode where players can engage in fast, fluid and frenetic combat to work together and achieve success. Utilizing combat skills, strategies, weapons and abilities gained from the field, players must coordinate to take down overwhelming forces.

Mass Effect: Andromeda is developed by BioWare and is available now on Origin for PC, Xbox One and PlayStation 4 in North America and starting March 23rd in Europe.

About Electronic Arts

Electronic Arts (NASDAQ:EA) is a global leader in digital interactive entertainment. The Company delivers games, content and online services for Internet-connected consoles, personal computers, mobile phones and tablets. EA has more than 300 million registered players around the world.

In fiscal year 2016, EA posted GAAP net revenue of $4.4 billion. Headquartered in Redwood City, California, EA is recognized for a portfolio of critically acclaimed, high-quality blockbuster brands such as The Sims™, Madden NFL, EA SPORTS™ FIFA, Battlefield™, Dragon Age™ and Plants vs. Zombies™. More information about EA is available at www.ea.com/news.

EA, BioWare, Mass Effect, Mass Effect: Andromeda, EA SPORTS, Origin, The Sims, Dragon Age, Plants vs. Zombies, and Battlefield are trademarks of Electronic Arts Inc.. John Madden, NFL, and FIFA are the property of their respective owners and used with permission.

EN
21/03/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Electronic Arts Inc.

Wedbush Research
  • Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
HURN HURON CONSULTING GROUP INC.
GME GAMESTOP CORP. CLASS A
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BZH BEAZER HOMES USA INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
INOD INNODATA
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
CVCO CAVCO INDUSTRIES INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ROKU ROKU INC. CLASS A
ISR ISORAY
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
UBER UBER TECHNOLOGIES INC.
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
U UNITY SOFTWARE
TVTX TRAVERE THERAPEUTICS INC
PLTR PALANTIR TECHNOLOGIES
VRDN VIRIDIAN THERAPEUTICS INC
IMNM IMMUNOME
PLTK PLAYTIKA HOLDING
RBLX ROBLOX
DAWN DAY ONE BIOPHARMACEUTICALS INC
STX SEAGATE TECHNOLOGY HLDGS PLC
ATXS ASTRIA THERAPEUTICS INC
GFS GLOBALFOUNDRIES INC
GMTX GEMINI THERAPEUTICS INC
VIGL VIGIL NEUROSCIENCE INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
APGE APOGEE THERAPEUTICS INC
SKLZ SKILLZ INC
EMBRAC B EMBRACER GROUP AB
DNTH DIANTHUS THERAPEUTICS INC
TLX TELIX PHARMACEUTICALS LIMITED
MAZE MAZE THERAPEUTICS INC
Alicia Reese ... (+3)
  • Alicia Reese
  • Kade Barr
  • Matthew McCartney

ResearchPool Subscriptions

Get the most out of your insights

Get in touch